Aug 27 |
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
|
Aug 15 |
AEMD: Oncology Trial Advancing; Approval from 2nd Site
|
Aug 14 |
Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript
|
Aug 14 |
Aethlon Medical GAAP EPS of -$0.34 misses by $0.02
|
Aug 14 |
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
|
Aug 13 |
Aethlon Medical Q1 2025 Earnings Preview
|
Aug 13 |
Aethlon Medical receives ethics committee approval for trial of cancer treatment
|
Aug 12 |
Aethlon Medical receives second ethics committee approval for Hemopurifier cancer trial
|
Aug 12 |
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
|
Aug 12 |
Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
|